MENU
Aim higher

OxidoCurin

Targets and biomarkers of the novel anticancer compounds inducing oxidative stress in cancer cells

We will further develop the novel anti-cancer lead compound LCTA2290 and its analogs: 1) Experimentally validate the target, identified during the first phase of the project – thioredoxin reductase 1 (TrxR1); 2) Identify the additional target(s) using state-of the-art TPP methodology; 2) Elucidate the mechanism of interaction of lead compound with the target(s) and the mechanism of action; 4) Identify biomarkers of sensitivity and resistance of cancer cells and the mechanism of possible toxicity
Acronym: 
OxidoCurin
Project ID: 
11 481
Ranking: 
8
Cut-off: 
7
Start date: 
01-08-2017
Project Duration: 
36months
Project costs: 
1 410 750.00€
Technological Area: 
Gene Expression, Proteom Research
Market Area: 
Therapeutic services